1. Introduction {#s0005}
===============

Poxviruses engineered to express foreign gene products are established tools for the development of novel vaccines and therapeutics in biomedical research. Large packaging capacity for heterologous DNA, strict virus-specific control of recombinant gene expression, lack of virus persistence in the host, immunogenicity and efficacy as vaccine, and ease of vector and vaccine production were important contributors to this success story. Concerns about the safety of conventional vaccinia viruses as smallpox vaccine have been addressed by the study of replication defective viruses unable to produce infectious progeny in human cells. Today, the highly attenuated vaccinia virus strain MVA can be considered as one of the vaccine viruses of choice in preclinical and clinical research. MVA is replication-deficient in cells of mammalian origin and fails to produce many of the virulence factors encoded by conventional vaccinia virus. Because of its safety for the general environment MVA can be handled under conditions of biosafety level 1 (BSL-1). Nonreplicating MVA can enter any target cell and activate its molecular life cycle to express all classes of viral and recombinant genes. Therefore, recombinant MVA have been established as an extremely safe and efficient viral vector system for basic research and for the development of vaccines suitable for industrial scale production. Here, we review the development of MVA as product from serial tissue culture passage in chicken embryo fibroblasts (CEF), its key biological properties, and recent accomplishments in vaccine research using recombinant MVA.

2. History and Development of MVA {#s0010}
=================================

2.1. Ancestry and Generation by Serial Passage {#s0015}
----------------------------------------------

Modified Vaccinia virus Ankara (MVA) was developed by serial passage in chicken fibroblast tissue culture to serve as safer vaccine during the last years of the WHO smallpox eradication campaign. Its ancestor virus is the vaccinia virus strain Ankara which was originally propagated on the skin of calves and donkeys at the Turkish vaccine institute in Ankara for smallpox vaccine production. In 1953, the vaccinia virus strain Ankara was brought to Munich and added to the strain collection of the Institute for Infectious Diseases and Tropical Medicine at the University of Munich. Herrlich and Mayr cultivated the virus on the chorioallantois membranes (CAM) of embryonated chicken eggs and therefore named it as Chorioallantois Vaccinia virus Ankara (CVA) ([@bb0485]). At the Bayerische Landesimpfanstalt München (Bavarian State Institute for Vaccines), CVA was grown on the skin of calves to manufacture smallpox vaccine for the vaccination campaigns in Munich in 1954/1955. In addition, at the University of Munich, CVA was tested in passage experiments in various tissue cultures to study the genetic stability and the evolution of orthopoxviruses. [@bb0695] reported that 371 passages of CVA in primary CEF had resulted in the development of an infection phenotype with restricted host (cell) tropism and it was discussed that similar biological properties were known from poxviruses that are highly adapted to specific hosts, e.g., variola virus (VARV) to humans or fowlpox virus to chicken. Successive passage of vaccinia virus in minced chicken embryo tissue had been described as successful strategy for in vitro amplification of the smallpox vaccine virus in a culture system ([@bb0895], [@bb0900]). The serial passage of CVA in CEF was further continued by Anton Mayr and colleagues and, in 1968 after the 516th passage on CEF, the virus was renamed Modifiziertes Vakziniavirus Ankara (MVA) and provided to the Bavarian State Institute for Vaccines to test its suitability for smallpox vaccine production ([@bb1020]).

2.2. Early Characterization of Biological Properties {#s0020}
----------------------------------------------------

Phenotypic changes relating to the repeated passage of the CVA virus in CEF cultures were first observed upon infection of the embryonated egg. For many years, CAM inoculations were the gold-standard experimental system for the phenotypic study of various poxviruses ([@bb0420], [@bb0425], [@bb0700]). MVA infection is characterized by the formation of small proliferative lesions on the CAM. In contrast, considerably larger CAM lesions with variable size areas of central necrosis are typically found with CVA or other conventional vaccinia viruses ([@bb0485]). Interestingly, the CAM lesions of MVA were noted to closely resemble those induced by variola or fowlpox viruses following egg inoculation ([@bb0695], [@bb1020]). In addition, it was observed early on that MVA had lost the capacity of vaccinia virus to cause prominent cytopathic effects and/or to form plaques in first-generation tissue cultures such as CEF, primary bovine, or porcine kidney cells, or human HeLa cells ([@bb0695]). The most characteristic changes in the in vivo behavior of the virus were reported from experimental inoculations of rabbits (German Great White) ([@bb0705], [@bb1020]). Intradermal infections or cutaneous infections by scarification with conventional vaccinia virus (VACV) result in the formation of typical skin lesions. Such lesions were totally absent following inoculation with MVA suggesting a substantial loss of virulence upon in vivo infection. These data were confirmed by the finding that newborn (strain NMRI; 1--3 days old) or adult mice (12--15 g) survived intracerebral inoculations of MVA at doses that resulted in 100% mortality following CVA infection ([@bb0705], [@bb1020]). The inability of MVA to induce primary reactions with pock lesions forming upon intradermal or cutaneous inoculation was also confirmed in the cynomolgus monkey model (*Macacus fascicularis*). Macaques tolerated intracranial inoculations with MVA without obvious adverse effects, whereas animals injected with CVA developed severe systemic disease. Moreover, intradermal or intramuscular vaccination with about 2 × 10^5^ infectious units (IU) of MVA vaccine protected macaques from severe disease following intravenous challenge with VARV strain Madras 1965 ([@bb0705], [@bb1020]). These data from early preclinical characterization in laboratory animals already suggested that MVA had maintained immunogenicity as vaccine but demonstrated a dramatic loss of virulence. Upon the 516th CEF passage the virus was renamed MVA and transferred to the Bavarian State Vaccine Institute in Munich for evaluation as safer smallpox vaccine in clinical trials.

2.3. Early Use as Safe Vaccine Against Smallpox {#s0025}
-----------------------------------------------

The first MVA vaccine preparation to be tested in humans was produced in CEF cultures and contained 10^6^  IU MVA/mL ([@bb1020]). In first attempts, the use of this vaccine by scarification failed to induce any kind of skin reactions and the application by intracutaneous inoculation (0.2 mL vaccine suspension containing 2 × 10^5^  IU MVA) was chosen for first clinical testing and primary vaccination of 107 individuals aged 2--38 years ([@bb1020]). After 4--6 days, minor local reactions developed at the site of injection with redness and swelling of the skin of the forearm. However, the investigators observed no pock lesions or other symptoms normally associated with smallpox vaccination and none of the 107 individuals developed fever (body temperature ≥ 38 °C). Interestingly, it was noted that the MVA application failed to induce circulation antibodies that inhibited the hemagglutination by VACV. Thus, the efficacy of immunization was tested with secondary vaccination by scarification using VACV strain Elstree in 64 of the 107 individuals that had received MVA for primary vaccination. Skin reactions typical for follow-up smallpox vaccinations were noted in 62 of 64 patients and suggested a successful primary immunization with the MVA vaccine. These data supported further clinical development of MVA as smallpox vaccine and, following the testing in more than 7000 patients ([@bb1025]), the Bavarian State Vaccine Institute in Munich obtained the first marketing authorization for MVA as primary prevaccine against smallpox in Germany in 1977 (Paul-Ehrlich-Institut, 31.01.1977). Until 1980, the MVA smallpox vaccine was given to more than 120,000 humans without documentation of severe adverse events otherwise associated with the use of conventional VACV vaccines ([@bb0690]). Immunizations with this first licensed MVA vaccine stopped with the end of the smallpox vaccination program in Germany.

2.4. The Genome of MVA {#s0030}
----------------------

Only a few years later, targeted genetic modification of the vaccinia virus genome became possible and the concept to generate recombinant viruses for gene expression or vaccination also restored interest in MVA. Restriction mapping of the MVA genome was based on the clonal virus isolate F6 from the 572nd CEF passage of MVA and revealed alterations in the MVA genome that are the likely genetic basis for attenuation and growth restriction ([@bb0750]). Comparison to the genome maps of CVA ancestor viruses revealed that the MVA genome harbors large deletions and mutations affecting many genes with functions in virus--host interaction ([Fig. 1](#f0005){ref-type="fig"} ). First important observations included (i) the failure to rescue productive MVA growth in cells of human origin by restoring the VACV host range gene K1L despite presence of the second VACV host range gene *C7L* with the MVA genome; (ii) the absence of the gene for the major VACV A-type inclusion body protein and the lack of this protein among the polypeptides made in MVA-infected cells; (iii) the demonstration that the coding sequences of the VACV hemagglutinin (HA) started right adjacent to deletion III within the MVA genome which a few years later allowed to identify the truncation of the HA promoter sequence explaining for the HA-negative phenotype of MVA and the inability to detect HA-specific antibodies upon MVA immunization ([@bb0030]). Notably, these early findings were further complemented by the elucidation of the full-length sequence of the MVA genome ([@bb0035]) and the discovery that MVA lacks important immunomodulatory genes ([@bb0090]).Fig. 1Generation of Modified Vaccinia virus Ankara (MVA) from ancestor virus Chorioallantois Vaccinia virus Ankara (CVA): Continuous serial passages of CVA in CEF resulted in significant loss of genetic information (\~ 30 kb) in the genome of MVA. as demonstrated by the occurrence of by six major deletions (I--VI) relative to the CVA genome.

2.5. First Recombinant MVA {#s0035}
--------------------------

The highly attenuated phenotype of the virus also encouraged the evaluation of MVA as an expression vector. Yet, MVA cannot productively replicate in most cells of mammalian origin and high-level expression of recombinant genes was doubtful because other host range mutants of VACV are inhibited already early in their life cycle ([@bb0265], [@bb0270]). The coding sequences for the *Escherichia coli* enzymes β-galactosidase and guanine-phosphoribosyl-transferase served as the first heterologous genes to be inserted and expressed at the site of deletion III in the MVA genome ([@bb1045]). Surprisingly, the production of early and late viral proteins turned out to be unimpaired in MVA-infected human cells ([Fig. 2](#f0010){ref-type="fig"} ). Indeed, the unique ability to efficiently express viral and recombinant genes supported its general application as exceptionally safe viral vector. To ascertain whether MVA vectors would be applicable for immunization experiments with recombinant antigens, a first MVA vector vaccine was constructed and tested that simultaneously expressed the HA and nucleoprotein (NP) genes of influenza A virus ([@bb1050]). The recombinant MVA was found to be immunogenic, since vaccination of mice by various routes resulted in high levels of serum antibodies that inhibited hemagglutination by influenza A virus. Moreover, the vector vaccine also elicited strong cytotoxic T cell responses directed to both influenza virus proteins. Importantly, animals could be completely protected against a lethal respiratory tract influenza challenge following single inoculations with relatively low doses of the recombinant MVA vaccine. To generate these first MVA vectors, the foreign gene sequences were targeted precisely to the site of the naturally existing deletion III in the MVA genome. This strategy in designing the vector was to avoid unnecessary changes in the genotype and phenotype of the resulting recombinant MVA. The development of other recombinant MVA vaccines with heterologous genes from simian immunodeficiency virus (SIV) or parainfluenza virus 3 inserted in deletion III rapidly followed ([@bb0500], [@bb1200]). Also, the natural deletion II within the MVA genome was successfully used as insertion site to express recombinant bacteriophage T7 RNA polymerase ([@bb1055]). In addition, the thymidine kinase locus, a well-exploited insertion site in replication-competent VACV vectors, likewise, served to generate recombinant MVA delivering antigens of HIV-1 or *Plasmodium berghei* ([@bb0465], [@bb0930]).Fig. 2Schematic representation of the nonpermissive life cycle of MVA in cells of mammalian origin. While MVA does not productively replicate in most mammalian cells, it can efficiently enter any cell and start its cascade-like life cycle resulting in unimpaired expression of viral early and intermediate genes, synthesis of viral genomic DNA, and the abundant expression of viral late genes. Thus, foreign and MVA proteins are efficiently produced and the block of the MVA life cycle occurs at the step of virion assembly resulting in assembly of immature virus particles that are not released from the infected cell.

3. MVA as Tool for Research in Poxvirus Biology {#s0040}
===============================================

Poxviruses including the prototype orthopoxvirus VACV are excellent models to study virus--host interactions. VACV can efficiently antagonize the activity of interferons (IFNs), cytokines, chemokines, and innate immune signaling (for review, see [@bb0965]). Hereby, VACV exploits the expression of soluble-binding proteins and receptor antagonists. Other viral immune evasion proteins work intracellularly to inhibit apoptosis or to interfere with host signaling pathways activating antiviral immune mechanisms. Notably, of the many VACV genes involved in immune evasion, most are inactivated or truncated in the MVA genome ([@bb0035]). Interestingly, early studies by Mayr and coworkers had suggested distinct immune stimulatory activities associated with experimental MVA inoculations ([@bb0705]). E.g., intraperitoneal application of virus to mice enhanced the in vivo clearance of carbon marker particles from the blood of the animals suggesting an increased phagocytic activity of immune cells 2 days after MVA inoculation. In addition, intranasal delivery of MVA to rabbits resulted within hours in the induction of "serum interferons" that efficiently inhibited sindbis virus replication in an in vitro infection assay. In the more recent past, various studies further elucidated the mechanisms of MVA-mediated induction of type I IFNs following in vitro and in vivo infections ([@bb0090], [@bb0190], [@bb0220], [@bb0520], [@bb1145], [@bb1150]). Indeed, the lack of many immune evasion factors and the failure of MVA infection to interfere early with key host (cell) defence mechanisms may explain the severe growth restriction of MVA, its high attenuation upon in vivo infection and its immunogenicity when used as vaccine. Moreover, due to the extensive loss of genetic information MVA may serve as a particularly useful tool to study VACV host-regulatory genes. Obviously, there are several pathways of the host (cell) defence that are targeted by multiple VACV proteins and the phenotype of a VACV single gene mutant may be masked by the complementary function of (an)other viral gene(s) ([@bb0235]). There are three obvious strategies using MVA to elucidate on functions of selected VACV host-interaction factors: (i) the few remaining regulatory genes in the MVA genome can be targeted for inactivation, (ii) candidate VACV genes missing in MVA are reinserted in the genome to rescue a host-interaction phenotype, or (iii) a combination of these latter approaches may serve to investigate putatively complementary gene functions. In the following we describe some principles learnt by MVA research that may help to better understand the regulation of virus--host interactions and likely influence safety and immunogenicity of VACV-based vaccines and therapeutics ([Fig. 3](#f0015){ref-type="fig"} ).Fig. 3Selected host-regulatory genes functionally maintained in the MVA genome: a schematic representation of the MVA genome is shown on the *top*. (A) Viral genes regulating the intracellular host tropism (host range genes) include the open reading frames C7L, F1L, E3L, and B18R. (B) Viral inhibitors of host inflammatory responses and host NF-kB signaling are highlighted by the MVA regulatory genes C12L, C6L, K7R, A41L, A46R, and B16R. (C) VACV N1L, M2L, and K1L genes are deleted or truncated in the MVA genome. Functional repair of these genes in the MVA genome may serve as example for the use of MVA in research addressing the regulation of VACV immune evasion or host tropism.

3.1. MVA Genes Regulating the Host Cell Tropism {#s0045}
-----------------------------------------------

One most striking feature of MVA is its inability to replicate in most cells of mammalian origin ([@bb0140], [@bb0255], [@bb0750]). In contrast, wild-type VACV has a broad cellular host range and productively infects various cell substrates ([@bb0265]). It is noteworthy that poxvirus infections do not rely on the availability of specific cellular receptors but the viruses can efficiently bind to and enter many different cells from diverse animal species. After entry, however, the success of VACV replication depends on the functional activity of a subset of viral genes, the so-called "host range" genes (for review, see [@bb0115], [@bb0460], [@bb0715]). These viral genes encode regulatory proteins that control the intracellular host defence, e.g. by manipulation of the sensing of viral pathogen associated molecular patterns, the signal transduction, the cell cycle, or the onset of programmed cell death. Some eminent viral regulators of intracellular host tropism are still functional in the MVA genome and include the proteins C7, K3, E3, F1, and B18 (68K) (following the nomenclature as established for the genome of VACV strain Copenhagen; [@bb0400]).

The VACV genes *K1L* and *C7L* (encoding the VACV proteins K1 and C7) are known to control virus replication in mammalian cells and both gene functions need to be inactivated to restrict the growth of wild-type VACV ([@bb0390], [@bb0855]). Already early work by Drillien and coworkers suggested that the replication defect of a VACV host range mutant (in the absence of *K1L* and *C7L*) is established at the level of viral gene expression ([@bb0270]). However, the severe growth defect of the highly attenuated MVA is not rescued when its genome is engineered to contain functional copies of both *K1L* and *C7L* suggesting that additional viral factor(s) await discovery ([@bb0040], [@bb0750], [@bb1050]). However, a *C7L*-deleted MVA lacks late gene expression in human and murine cells and induces phosphorylation of eukaryotic translation initiation factor 2α (eIF2α). The deficiency of late gene expression and the phosphorylation of eIF2α in the absence of C7 can be prevented by K1 as shown by the reinsertion of the *K1L* gene into the genome of *C7L*-deleted MVA ([@bb0040]).The complementary function of *K1L* and *C7L* is intriguing because the two genes and encoded proteins are unrelated in sequence. Interestingly, recent studies identified the human genes SAMD9 (sterile alpha motif domain-containing 9) and WDR6 (tryptophan-aspartic acid repeat 6) as host restriction factors for poxviruses and as targets of C7 and K1 ([@bb0655], [@bb0950]). To date, rather little is known about the molecular functions of SAMD9 and WDR6, but it can be assumed that they act in (an) innate antiviral defense pathway(s) awaiting further elucidation.

The viral proteins K3 and E3 (encoded by *K3L* and *E3L* genes) are well-known intracellular inhibitors of IFN-induced antiviral activities of the host cell ([@bb0155], [@bb0195]). K3 has homology to the alpha subunit of eIF2α and serves as a pseudo-substrate for double-stranded RNA (dsRNA)-activated protein kinase (PKR) to prevent virus-induced phosphorylation of eIF2α by PKR. In turn, E3 can sequester dsRNA to inhibit the stimulation of PKR and to prevent activation of 2′-5′ oligoadenylate synthase and the endoribonuclease RNaseL. In addition, E3 has been described to independently inhibit the phosphorylation of the transcription factors IRF-3 and IRF-7 and thus to block the production of type I IFNs ([@bb0960], [@bb1215]). These IFNs evasion mechanisms provided by K3 and E3 substantially contribute to the broad cellular host range of VACV and numerous host range phenotypes of VACV mutants lacking *E3L* or *K3L* genes have been found ([@bb1175]). Interestingly, CEF-adapted MVA has maintained fully active *E3L* and *K3L* sequences. Indeed, a functional *E3L* gene is required for MVA replication in CEF where E3 functions as an inhibitor of apoptosis and/or IFN induction to allow for unimpaired late protein synthesis ([@bb0510]). In human HeLa, HaCat or 293T cells studies with an *E3L*-deleted MVA mutant (MVA-ΔE3L) revealed that E3 is also essential to secure viral intermediate and late protein synthesis by counteracting host cell-specific activation levels of antiviral pathways PKR or RNaseL ([@bb0670], [@bb0675]). MVA-ΔE3L also increased the type I IFN and/or chemokine production when compared to wild-type MVA in infections of primary murine fibroblasts or murine bone marrow-derived dendritic cells which is in agreement with the known activation of transcription factors IRF-3 and IRF-7 in the absence of E3 ([@bb0190], [@bb0520]). Likewise, apoptosis induction in MVA-ΔE3L infected murine fibroblasts required the proapoptotic cellular BH3-only protein Noxa which is well in line with the IRF-3/IFN-beta-mediated activation of Noxa ([@bb0220], [@bb0345]).

Cell death by apoptosis is an important defence mechanism to protect the host against viral infection. In turn, poxviruses have evolved specific viral proteins to inhibit the onset of programmed cell death and these regulatory proteins are relevant determinants of virus tropism at the cellular level ([@bb1080]). The VACV F1 protein (encoding gene *F1L*) is an antiapoptotic protein with Bcl-2-like structure proposed to block apoptosis by binding to the proapoptotic family protein Bak ([@bb0860], [@bb1155], [@bb1160]). *F1L* is also conserved in the MVA genome and *F1L*-deficient MVA (MVA-ΔF1L) induces enhanced apoptosis in HeLa cells and in mouse embryonic fibroblasts ([@bb0345]). Additional work with MVA-ΔF1L demonstrated that triggering of apoptosis predominantly requires the induction of the pro-apoptotic BH3-only protein Noxa which then activates proapoptotic Bak ([@bb0340]). Hereby, activation of Noxa was linked to the recognition of viral RNA and the upregulation of type I IFN signaling. Thus, the Noxa-dependent induction of apoptosis observed upon infections with MVA-ΔE3L ([@bb0345]) may be explained by the failure to sequester viral RNA in the absence of E3 resulting in strong activation of pro-apoptotic Noxa ([Fig. 4](#f0020){ref-type="fig"} ). Ankyrin repeat (ANK) motifs are found in many poxvirus regulatory proteins that determine the cellular host tropism and/or counteract antiviral host responses controlled by NF-kB signaling ([@bb0475]). Otherwise ANK motifs are described important for many protein--protein interactions and cellular ANK proteins are involved in diverse regulatory tasks including cellular transcription, cell cycle control, or cellular differentiation ([@bb0775]). The only ANK-containing protein encoded by the MVA genome is the 68-kDa Ankyrin-like protein (68k-ank; homologue to the VACV Cop *B18R* gene product). In addition to ANKs, 68k-ank contains an F-box-like PRANC (pox protein repeats of Ankyrin C-terminal) domain ([@bb0740]). MVA 68k-ank binds to cellular Skp1a and forms a Cullin-1-based SCF ubiquitin ligase complex in an F-box-dependent manner ([@bb0975]). A 68k-ank-deficient MVA mutant shows reduced transcription of intermediate and late viral genes and suffers from a drastically impaired late protein synthesis in human and murine cells ([@bb0980]). Thus, 68k-ank is essential for the completion of the MVA molecular life cycle. Interestingly, the F-box domain of 68k-ank is dispensable for rescue of the 68k-ank mutant phenotype suggesting multiple activities of this host-regulatory MVA protein.Fig. 4Role of the MVA regulatory proteins E3 and F1 within the intracellular virus life cycle: E3 can efficiently sequester dsRNA produced during infection to counteract the activation of the antiviral host enzymes OAS (2′-5′ oligoadenylate synthetase)/RNaseL (Ribonuclease L) or PKR (Protein kinase RNA-activated). Additional functions of the E3 protein are to prevent the activation of the host proapoptotic protein Noxa and to block the phosphorylation of the transcription factors IRF-3 and IRF-7 inhibiting the production of type I interferons. The MVA protein F1 can bind or prevent the activation of proapoptotic host proteins Bax/Bak or Noxa and acts as efficient inhibitor of cytochrome *C* release (Cyto *C*) and apoptosis induction at the level of host cell mitochondria.

MVA is intensely used as vector vaccine being tested against a variety of infectious diseases (see [Section 4](#s0055){ref-type="sec"}) and some cancers. However, we still know very little about the influence on MVA vaccine immunogenicity and vaccine efficacy with regard to these MVA proteins regulating the host cell tropism. Indeed, modulating the functional activity of these proteins could result in quite different outcomes. In one scenario, the inactivation of these regulators may further enhance MVA-mediated activation of the innate immune system and may lead to improved protective immunity; another possible scenario is reduced MVA vaccine efficacy because the deletion of some of these genes (e.g., *E3L*, *C7L*, *68k*-*ank*) may drastically impair viral replication, the levels of gene expression and MVA-mediated antigen synthesis

3.2. MVA Genes Regulating Inflammatory Response and Immunogenicity {#s0050}
------------------------------------------------------------------

In addition to regulatory genes targeting the host tropism, the MVA genome also contains a number of genes with known immunomodulatory functions. One interesting example is gene *B16R* encoding the VACV interleukin-1β receptor protein (IL-1βR). This viral cytokine-binding protein has high-specific affinity for IL-1β ([@bb0005], [@bb0985]) and is thought to play an important role in the regulation of inflammatory responses following VACV infection ([@bb0010]). Synthesis of IL-1βR could be demonstrated in various MVA-infected cultured cells ([@bb0090], [@bb1235]). Interestingly, primary murine myeloid dendritic cells are important IL-1β producer cells upon MVA infection but free IL-1β can be detected only in the absence of IL-1βR using the deletion mutant MVA-ΔIL-1βR. Immunizations with this MVA deletion mutant led to significantly enhanced virus-specific CD8 + T-cell responses and increased protective capacity against lethal challenge infection with virulent VACV strain Western Reserve (WR) ([@bb1000]). In addition, the gene sequence encoding the VACV interleukin-18 (IL-18) binding protein (IL-18BP; *C12L* gene) is also functionally retained in the MVA genome ([@bb0955]). VACV IL-18BP binds soluble IL-18 and prevents it to reach its cellular receptor targeting the proinflammatory and antiviral function(s) of this cytokine ([@bb0105], [@bb0130], [@bb1060]). The possibility to enhance vaccine immunogenicity by inactivation of the IL-18BP gene in MVA was investigated in two previous vaccination studies in mice. Cottingham and coworkers found no significant difference in VACV-specific T cell responses when comparing vaccines based on MVA mutated in *C12L* or wild-type MVA ([@bb0180]). A second study demonstrated functional activity of the MVA IL-18BP and immunizations with the MVA deletion mutant increased VACV epitope-specific CD8 + and CD4 + T-cell responses and protective capacity against a VACV challenge infection ([@bb0325]). To diminish the inflammatory host response, another strategy of VACV is the production of secreted viral chemokine receptor proteins which prevent the chemokine-mediated recruitment of leukocytes ([Fig. 5](#f0025){ref-type="fig"} ) ([@bb0015], [@bb0435], [@bb0810]). Interestingly, MVA has lost much of this VACV immune evasion activity. MVA efficiently induces chemotaxis and triggers the rapid immigration of leukocytes to the site of in vivo inoculation ([@bb0645]). Yet, MVA still produces the secreted protein A41 which binds chemokines with relatively low affinity suggesting another functional mechanism than just blocking the binding of chemokines to their cellular receptors ([@bb0045]). Moreover, deletion of the *A41L* gene in MVA improved the CD8 + T-cell immunogenicity and the protective capacity of vaccination ([@bb0175]).Fig. 5Remaining MVA inhibitory proteins targeting the innate NF-kB signaling pathway by MVA regulatory proteins: *IRAKs*, interleukin-1R-associated kinases; *TRAF*, TIR-domain-containing adapter-inducing interferon-β; *IKK*, inhibitor of nuclear factor kappa-B kinase; *NF-kB*, nuclear factor kappa-B; *TRIF*, TIR-domain-containing adapter-inducing interferon-β; *TRAM*, TRIF-related adaptor molecule; *TIRAP*, Toll-interleukin 1 receptor (TIR) domain-containing adapter protein; *MyD88*, myeloid differentiation primary response gene 88; *IL-1R*, interleukin-1 receptor; *TLRs*, Toll-like receptors.

VACV encodes an impressive variety of intracellular virus proteins that can inhibit the host signaling pathways for NF-kB and IRF-3 (for review, see [@bb0965]). Together these proteins serve to dampen the innate host response by blocking the induction of type I IFNs, chemokines, and proinflammatory cytokines. MVA fails to functionally produce a substantial number of these inhibitory proteins including A52, B14, C4, C16, K1, M2, and N1. Indeed, MVA infection induces the activation of NF-kB ([@bb0820]) and the reinsertion of the original VACV gene sequences into the MVA genome allowed to further elucidate the function of K1 and M2 as NF-kB inhibitors ([@bb9005], [@bb9010]). Other inhibitory genes, such as *C6L*, *K7R*, *A46R*, and *A49R*, are fully conserved in MVA. Interestingly, the removal of *C6L*, *K7R*, or *A46R* from the MVA genome is reported to contribute to higher frequencies of antigen-specific CD8 + and CD4 + T cells, enhanced polyfunctionality of T cells and higher antigen-specific antibody titers when tested in recombinant MVA-producing HIV candidate antigens ([@bb0360], [@bb0365], [@bb0370]). A similar improved immunogenicity is also described for a recombinant MVA-HIV virus deleted in the *N2L* gene ([@bb0375]). These data suggest the functional activity of MVA N2 despite the fact that the MVA gene harbors an in-frame deletion causing the loss of five amino acids (aa 31--35). VACV N2 is an interesting regulatory protein because it acts as inhibitor of IRF-3 activity within the nucleus of infected cells ([Fig. 6](#f0030){ref-type="fig"} ) ([@bb0335]).Fig. 6Schematic overview depicting the synthesis of MVA regulatory proteins involved in modulation of the host response: Most of these host-regulatory proteins are produced early during MVA infection associated with the rapid intracellular activation of innate host responses including the induction of apoptosis, interferons and interferon stimulated gene products or inflammatory cytokines. Interestingly, a few viral inhibitory proteins, such as the viral receptor of IL-1β (B16), are produced at late times of infection suggesting a predominantly extracellular function of these inhibitors of the host response.

4. Recombinant MVA Vaccines Against Infectious Diseases {#s0055}
=======================================================

4.1. Vector Technologies and Requirements for Clinical Use {#s0060}
----------------------------------------------------------

Shortly after the eradication of smallpox, VACV acquired a new mission as eukaryotic cloning vector for the expression of heterologous genes. Homologous recombination that frequently occurs between VACV genomes within an infected cell was discovered to allow for efficient insertion of foreign DNA into the VACV genome ([@bb0680], [@bb0840], [@bb1190], [@bb1195]). This technology enabled the development of new recombinant vaccines that could be beneficial to decrease the impact of various infectious diseases. Over the years replication-competent recombinant VACV has been successfully introduced for use in veterinary medicine as accomplished with the recombinant VACV vaccines against rabies ([@bb0095], [@bb0295], [@bb0570]). The application of recombinant VACV for vaccination of humans was lagging behind restricted due to the well-known side effects of VACV smallpox vaccines. In these circumstances the availability of replication-deficient VACV such as NYVAC or MVA has spurred the establishment of exceptionally safe next-generation poxviral vectors ([@bb1045], [@bb1075]). The technology for recombinant MVA has been adapted from VACV. The still most frequently and effectively practiced strategy to generate recombinant poxviruses employs homologous DNA recombination in infected cells, a relatively frequent event during VACV genome replication (0.1%) ([@bb0685], [@bb0800]). Recombination is typically directed by a gene transfer plasmid. For transcriptional control of foreign genes, various virus-specific promoters are used to achieve moderate to strong expression during the whole virus replication cycle ([@bb0055], [@bb0145], [@bb0200], [@bb0225], [@bb0230], [@bb1170], [@bb1200]). Usually, the plasmid carries the specific expression unit with a virus-specific promoter next to the multiple cloning site for insertion of various foreign gene sequences and selectable markers to facilitate the clonal isolation of recombinant MVA ([@bb0685], [@bb9020]). The foreign gene sequences and the marker gene are flanked on both sides by genomic MVA sequences that direct the recombination of the expression cassette to favored loci in nonessential regions of the MVA genome. In MVA, the sites of major deletions are suited for the insertion of foreign gene sequences without affecting essential regions in the MVA genome ([@bb1045], [@bb1055]). Until today, deletion site III serves as one of the most frequently used insertion loci ([@bb0605], [@bb0970], [@bb1120]). In addition, standard insertion sites used in conventional VACV, the thymidine kinase gene locus (*J2R*) and the HA gene locus (*A56R*), were readily established for the construction of recombinant MVA ([@bb0030], [@bb0930]). Moreover, due to the high fidelity of homologous recombination also small nonessential regions between MVA genes can be used to introduce heterologous DNA for vector construction ([@bb1210]). Multiple insertion sites may allow for integration of various expression units for foreign genes in the same MVA genome when opting for multivalent recombinant vaccines. For the generation of recombinant MVA, cells are infected with MVA and simultaneously transfected with the respective MVA transfer plasmid to allow for homologous recombination ([@bb0615], [@bb9020]). Recombinant MVA viruses are clonally isolated in repetitive cell culture passages screening for specific selection markers. Different protocols have been established to allow differentiation between wild-type and recombinant MVA. Very first approaches took advantage of specific enzymes that allow for color discrimination. Here, the transfer vector contains an antibiotic selection marker or a reporter gene allowing the screening due to a change in phenotype such as coexpression of the *E*. *coli* β-galactosidase and β-glucuronidase ([@bb0135], [@bb0145]). Among the coexpressed antibiotic resistance markers, the *E*. *coli gpt* gene encoding the enzyme xanthine-guanine-phosphoribosyl-transferase is frequently used for purification of recombinant viruses by dominant positive selection for resistance against mycophenolic acid ([@bb0330], [@bb0515]). Staining procedures require additional time of tissue culture, supplementation of agar overlays, and the use of chromogenic substrates and antibiotics. Complementation of a defect in virus production is a faster and more convenient method to obtain recombinant MVA viruses. A first growth selection protocol was initiated using the VACV host range gene *K1L* to rescue recombinant MVA replication in rabbit kidney RK-13 cells ([@bb0995]). Blasco and Moss had introduced selection for VACV plaque formation through coinsertion of the F13L gene which was adapted to isolate MVA vector viruses ([@bb0100], [@bb0920]). Moreover, MVA mutant virus and a matching complementing cell line enables for growth selection based on the essential *D4R* gene function ([@bb0890]). Up to now, the generation of recombinant MVA viruses is based on well-established techniques for isolation of clonal viruses that include the use of serum-free media and marker-free recombinant viruses. Specific regulatory guidelines help to supervise the generation of recombinant vector vaccines suitable for applications in humans ([@bb0290]). Yet, in consequence, generation of recombinant MVA is to a certain extent more limited to the use of some preferred methods ([@bb0615]). E.g., one preferred scheme is the isolation of recombinant MVA through screening for transient cosynthesis of marker proteins without enzyme activity and not related to an antibiotic or chemotherapeutic resistance phenotype. Fluorescence proteins such as green or red fluorescent proteins are conveniently used as well-characterized inert marker proteins. Alternative procedures to engineer poxvirus genomes have been pioneered more recently. The entire VACV and MVA genomes were cloned as bacterial artificial chromosomes (BAC), which can be engineered in *E*. *coli* by homologous recombination with bacteriophage lambda-derived enzymes ([@bb0180], [@bb0240], [@bb0245]). The modified BAC clones can be used to produce pure recombinant poxvirus in mammalian cells with the initial assistance of a helper virus but without further requirements for plaque purification. Another up-to-date method, yet to be adapted to the construction of recombinant MVA, utilizes the CRISPR-Cas9 system to insert alternative gene sequences into the VACV genome ([@bb1225]). Importantly, independent of the methodology used for generation of a recombinant MVA virus any new vector virus has to be thoroughly quality controlled for genetic identity, purity, genetic stability, recombinant gene expression, and growth characteristics ([@bb0615]). Typically, the in vitro characterization already starts during the process of clonal isolation of MVA vector viruses by plaque purification. A collection of straightforward methodologies has been established to confirm genomic identity and the correct insertion of the target gene sequence within the MVA genome using finger-print PCRs to assess the insertion sites and the six naturally occurring deletion sites. Levels and kinetics of recombinant protein synthesis, the stability, or the posttranslational modification of the foreign target proteins are typically monitored using standardized in vitro infection experiments and antigen-specific immune detection assays (e.g., Western blotting). In this context, it is also important to analyze the growth capacities of recombinant MVA. The well-known replication deficiency of MVA in mammalian cells is a key biological characteristic of MVA and allows the genetically modified virus to be handled in Germany under conditions of BSL-1 with minimal potential biohazard to laboratory personnel, clinicians, patients, and the general environment ([@bb0125]). Therefore, new recombinant MVA are routinely tested for their growth characteristics in cells of human origin, preferably in cells with normal differentiation such as HaCat cells ([@bb0110]). This experimental assay serves to exclude that the target gene sequence inserted within the MVA genome influences the growth behavior and biological safety of MVA. Further growth analyses must confirm the replicative capacity of new recombinant MVA in cell cultures suitable for industrial scale production. In 2010, the European Medicines Agency (EMA) has released a guideline on quality, nonclinical, and clinical aspects of live recombinant viral vectored vaccines in Europe ([@bb0290]). At present, primary CEF remains the major cell substrate matching the requirements for the generation and manufacturing of recombinant MVA vector vaccines for clinical evaluation in humans. Several vaccine producers established methodologies under Good Manufacturing Practice (GMP) to allow for large-scale serum-free preparation and cultivation of primary CEF for MVA amplification. However, primary CEF are considered a demanding cell substrate for optimizing industrial virus productions. Thus, in the last few years, various efforts have been made to establish alternative production cell lines for MVA apart from the primary CEF. MVA can be efficiently replicated in different continuous avian cell lines based on chicken embryo, duck embryo, or quail embryo tissues using chemically defined media and bioreactor processes to replace primary CEF ([@bb0555], [@bb0660]). Moreover, it is encouraging that some of these designer cell lines have already been used to manufacture first candidate vaccines being approved for clinical evaluation ([@bb9000]).

4.2. Vector Vaccines Against Influenza {#s0065}
--------------------------------------

In medical research and development ongoing efforts focus on the study of candidate vaccines against infectious diseases that are more "complicated" to prevent, e.g., those caused by newly emerging pathogens such as severe acute respiratory syndrome coronavirus, West Nile virus (WNV), or avian influenza virus. For decades, the availability of a safe and efficient vaccine against different influenza viruses has been one of the biggest demands of public health systems. Until today, infection with seasonal influenza virus kills about 250,000--500,000 people every year. Here, the main risk groups comprise the elderly, immunocompromised and children, with the highest incidence of fatal outcome ([@bb0665]). Moreover, in addition to the circulating seasonal influenza viruses, there is a continuous threat of new pandemic influenza viruses that might arise from pigs or birds ([@bb0350], [@bb0480]). During the last century, there have been four pandemics that together caused more than 50 million deaths ([@bb0915]). Hence, it is not surprising that influenza was the target of the first recombinant MVA vaccine. This vector virus was designed to codeliver the influenza virus A/PR/8/34 (H1N1) antigens HA, and NP (MVA-HA-NP) ([@bb1050]). BALB/c mice immunized with MVA-HA-NP mounted efficient levels of HA-specific antibodies as well HA- and NP-specific CD8 + T cells. A single intramuscular immunization was sufficient to protect these mice against a lethal respiratory challenge with influenza virus A/PR/8/34. Subsequently, MVA-HA-NP was shown to induce mucosal immunity following oral immunization and to allow for partial protection against a heterologous influenza virus subtype H3N2 challenge infection ([@bb0075]). After these results from testing a first recombinant MVA-expressing influenza virus antigens, it took sometime to encourage a multitude of other experiments targeting influenza in veterinary as well as human medicine. Breathnach and coworkers characterized a recombinant MVA-producing HA or NP from equine influenza A virus H3N8. Vaccination of ponies with MVA-HA induced robust levels of antibodies and protected against challenge with influenza virus H3N8 A/equine/Kentucky/1/81. Also MVA-NP-vaccinated ponies did not show severe clinical symptoms upon influenza virus challenge infection suggesting the induction of cellular immune responses with protective capacity ([@bb0120]). Because of the zoonotic transmission and the pandemic potential of various highly pathogenic avian influenza viruses of the H5 subtype, the development of H5-specific vaccines for humans is considered a priority since 1997 ([@bb0205], [@bb1220]). Vaccine development is complicated by antigenically different clades of influenza viruses within the H5 subtype. In this context, Kreijtz and coworkers evaluated recombinant MVA expressing the HA genes of the two different influenza H5N1 viruses A/Vietnam/1194/04 and A/HK/156/97 (MVA-HA-VN/04, MVA-HA-HK/97) ([@bb0585], [@bb0590], [@bb0595]). Vaccination with either of the recombinant MVA efficiently induced antibody responses against the homologous influenza virus. Moreover, immunization with MVA-HA-VN/04 (clade 1) was able to activate antibodies not only against the homologous virus but also to A/HK/156/97 (clade 0) and to a lesser extent to A/Indonesia/5/05 (clade 2.1). This potent activation of influenza virus-neutralizing H5-specific antibodies correlated with protective efficacy against homologous and heterologous challenge infection ([@bb0585]). Interestingly, the exceptional immunogenicity of the HA antigen of influenza A/Vietnam/2004 was confirmed in another study comparing recombinant MVA vaccines expressing HA antigens from various influenza A viruses H5N1 (clades 0, 1, 2.1, 2.2, 2.3) ([@bb0495]). MVA-HA-VN/04 also proved immunogenic and protective when tested as single-shot vaccine in chickens against challenge with the highly pathogenic avian influenza virus A/duck/Vietnam/TG24-01/05 ([@bb1105]).

In cynomolgus macaques, prime-boost immunization with MVA-HA-VN/04 was able to protect the animals against homologous virus A/Vietnam/1194/04 and infection with clade 2.1 influenza virus A/Indonesia/5/05. The absence of virus infected cells in the lungs and the lack of fever and severe interstitial pneumonia highlighted the induction of solid protective immunity in vaccinated animals ([@bb0595]). Results from further evaluation in mice also demonstrated the efficacy of MVA-HA-VN/04 vaccines in dose-sparing and single-shot immunizations. Here, minimal requirements for induction of protection against homologous and heterologous influenza virus challenge infections include a single immunization with 10^6^  pfu (plaque-forming units) MVA-HA-VN/04 or prime-boost immunizations with 10^4^  pfu MVA-HA-VN/04. Of note, in some experiments, protection was observed in the absence of detectable HA-specific antibodies. These data look very encouraging with regard to pandemic risks where a vaccine has to protect rapidly and at minimal doses ([@bb0590]). In this context recombinant MVA expressing the HA from pandemic H1N1 A/California/04/2009 turned out to be highly immunogenic and protective when tested in the mouse model and ferrets ([@bb0490], [@bb0600]). In ferrets, prime-boost vaccination with MVA-HA-CA/09 efficiently activated virus-specific antibodies, reduced the clinical signs after challenge infection with A/Netherlands/602/2009, and protected against severe histopathological changes in the lungs. Two immunizations also significantly lowered the presence of infectious virus in the upper and lower respiratory tract ([@bb0600]). Due to these promising results from in vivo preclinical evaluation, a first-in-man phase I/IIa clinical study of MVA-HA-VN/04 has been facilitated ([@bb0605]). The vaccine was safely tolerated and serious side effects were not observed. Furthermore, this candidate vaccine proved to be immunogenic in all individuals enrolled in this study. MVA-HA-VN/04 efficiently activated antibodies cross-reacting with homologous and heterologous H5 subtype influenza viruses and with the recently emerging highly pathogenic avian influenza virus subtype H5N8 ([@bb0215]). Of note, prime-boost applications via the intramuscular route induced levels of influenza H5N1-specific antibodies that raise expectations for protective capacity. Interestingly, booster vaccinations allowed for a remarkable enhancement of H5N1 specific antibodies when given 12 months after primary immunization. These results firstly describe a major benefit of booster vaccinations with recombinant MVA using an extended time period between primary and secondary immunization ([@bb0605]). Future clinical studies using similar regimens might help to develop new vaccination strategies. Overall, the induction of robust levels of influenza HA-specific antibodies can be expected to afford cross-protective immunity to viruses of the same influenza virus subtypes. In addition, MVA-mediated delivery or codelivery of influenza virus T cell antigens is being considered to possibly confer broader protection against various subtypes (for review, see [@bb0020]). Probably, most extensively tested as T cell vaccine is a recombinant MVA vaccine expressing the influenza virus NP and Matrix 1 (M1) proteins (MVA-NP+M1; [@bb0635], [@bb0785]). This candidate vaccine was also shown to induce influenza-specific CD8 + T cells in phase I/IIa clinical studies and to protect humans from an experimental influenza challenge infection ([@bb0080], [@bb0650]). Finally, aiming on broadly protective "universal" influenza virus vaccines Kamlangdee and coworkers tested an innovative recombinant MVA expressing an in silico generated synthetic H5 antigen representing a mosaic sequence of more than 2100 H5N1 viruses ([@bb0560]). Interestingly, this candidate vaccine protected mice against H5N1 viruses from all clades but also against infection with influenza virus A/PR/8/34 (H1N1). Taken together these highly encouraging data support the clinical evaluation of existing MVA candidate vaccines and the further development of novel recombinant MVA against influenza.

4.3. Vector Vaccines Against AIDS, Tuberculosis, and Malaria {#s0070}
------------------------------------------------------------

A safe and effective human immunodeficiency virus (HIV) vaccine is urgently needed to control the worldwide HIV epidemic. However, the development of a vaccine against AIDS represents a substantial scientific challenge related to HIV antigenic variability, the lacking understanding of immune correlates for protection, limitations of available animal models, and the enormous constraints associated with the probable need for multiple large-scale clinical trials in different parts of the world (for review, see [@bb0320]). Moreover, the fragile immune system of HIV-infected individuals sets high standards to candidate vaccine safety. In the recent past, highly attenuated poxviruses continued to play a major role in the international search for an AIDS vaccine also taking advantage of established technologies for vector vaccine production at industrial scale. Different recombinant MVA-expressing HIV proteins have undergone preclinical and clinical testing for the activation of protective immune responses against AIDS often in combination with DNA-based and/or adenoviral vector vaccines (for review, see [@bb0525], [@bb0825]). Recombinant MVA vaccines targeting different HIV-1 subtypes continued to prove safe and immunogenic in additional clinical studies ([@bb0405], [@bb0545], [@bb0790], [@bb0815]). Important new findings included data for the induction of high levels of antibody-dependent cellular cytotoxicity-mediating antibodies and months durability of the vaccine-induced HIV Env-specific antibody responses. In this context, a necessary target antigen comprises the immunodeficiency virus envelope (Env) protein, as it could be shown to elicit antibody responses with enhanced protective capacity in nonhuman primate chimeric simian/human immunodeficiency virus (SHIV) or SIV challenge infection models ([@bb0060], [@bb0065], [@bb0910]). Recent approaches are working on the induction of broadly neutralizing antibodies at the mucosal site of viral entry based on Env-specific vaccines. Other important HIV immunogens delivered by MVA candidate vaccines include Gag, Pol, and Nef proteins targeting the induction of HIV-specific CD4 + and CD8 + T cells ([@bb0415]). In addition, new synthetic HIV-specific "mosaic" immunogens are under evaluation as improved antigens for induction of CD8 + T cells ([@bb0830]). The large number of different HIV candidate vaccine necessitates the development of preclinical model systems to evaluate and select the most promising vaccine candidates. In many preclinical experiments, varying degree of protection against homologous immunodeficiency virus infection has been found, predominantly depending on the challenge virus and/or the animal model used for evaluation. However, HIV has an extraordinary genetic diversity and the "Holy Grail" AIDS vaccine would have to cross-protect against different HIV clades. A major scientific challenge is now to find appropriate antigens or epitopes that elicit a cross-protective immune response. For sometime, induction of cellular immunity was the primary focus of HIV vaccine development but the generation of broadly neutralizing antibodies is also believed to be indispensable ([@bb0250]). Previous data from two studies in the macaque model showed that booster vaccinations with oligomeric or native Env proteins enhance Env-binding and virus-neutralizing antibody responses primed by recombinant MVA vaccines, and suggest that such antibodies are indeed likely to play a role in vaccine-induced protection ([@bb0275]). Currently, SIV or SHIV challenge infections in different nonhuman primates are considered to be the most appropriate animal models to test for immunogenicity and efficacy. These models very closely mimic the pathogenesis of HIV infections in humans concerning viremia, progressive depletion of CD4 + T cells, and the clinical manifestation of AIDS ([@bb1100]). The thorough characterization of recombinant MVA candidate vaccines in the SIV model continues to further elucidate on the protective capacity of SIV antigen-specific immune responses ([@bb0150], [@bb0530], [@bb0630], [@bb1095]). Thus, these nonhuman primate models might allow for the generation of proof-of-concept data on antiviral immunity that effectively inhibits immunodeficiency virus replication and disease development.

In addition, MVA vector vaccines have proven to be excellent candidates for vaccine development against other infectious diseases with global impact such as tuberculosis and malaria (for review [@bb0720]). The incidence of disease caused by *Mycobacterium tuberculosis* is steadily increasing often on the basis of poverty-impaired health services, wide-spread HIV infection, or the emergence of resistant *M. tuberculosis*. In recent efforts to elicit more potent antimycobacterial immunity, MVA vector viruses served to identify new promising target antigens and resulted in the development of first subunit vaccines entering clinical testing ([@bb0730], [@bb0940]). Here, the conserved mycobacterial antigen 85A turned out to be a promising immunogen for induction of antigen-specific T cells against *M. tuberculosis*. A recombinant MVA candidate vaccine-expressing 85A under transcriptional control of the VACV early/late promoter P7.5 (MVA85A) has been extensively tested in preclinical models and phase I to phase IIb clinical studies. Vaccination of BALB/c mice with MVA85A induced both CD4 + and CD8 + T-cell responses and conferred protection against challenge with *M. tuberculosis* ([@bb0725]). Importantly, in an approach to efficiently trigger activation of 85A-specific cellular immune responses by vaccination, recombinant MVA85A has been successfully evaluated for boosting the immunogenic effects of a *Mycobacterium bovis* BCG primary immunization. Preclinical studies in different animal models, including mice, guinea pigs, nonhuman primates, and cattle, confirmed the protective efficacy of the heterologous BCG prime-MVA85A boost vaccination. In these experiments protection was associated with a reduction of bacterial loads in the lungs rather than with sterilizing immunity ([@bb0430], [@bb1180], [@bb1185]). Unfortunately, when testing BCG-MVA85A immunizations in a large phase IIb clinical trial in children in Africa there was no improvement compared to the conventional BCG only immunization schedule ([@bb1065]). MVA85A was well tolerated and immunogenic as shown by the induction of 85A antigen-specific CD4 + T cells. However, the immunizations demonstrated no significant efficacy against tuberculosis or *M. tuberculosis* infection. Nevertheless, the study provides an important and encouraging pool of safety data for a recombinant MVA candidate vaccine tested in more than 1300 infants. Overall, the results obtained from the clinical testing of MVA85A support the development of improved recombinant MVA85A candidate vaccines against tuberculosis but also including additional antigens of *M. tuberculosis*.

In 2013, there were more than 500,000 estimated deaths and about 200 million clinical illnesses due to malaria, the majority in central and southern Africa. Thus, an effective vaccine against malaria is urgently required ([@bb0505]). A variety of antigens from *Plasmodium falciparum* has been expressed and tested with recombinant VACV. The pathogenesis of malaria involves a complex life cycle including different blood and nonblood life stages of the parasites in the human host as well as in the mosquito host. A major challenge is the choice of optimal target antigens mediating protective immune responses against the multiple phases of malaria. Desirable targets should result in an efficient activation of humoral immunity as well as malaria-specific CD8 + T cells. In a landmark study, Schneider and coworkers had evaluated recombinant MVA vaccines in a mouse malaria model using *P. berghei*. The study demonstrated efficient induction of malaria-specific T cells that could be further enhanced by using DNA prime in combination with recombinant MVA as boosting agent. Of note, this study demonstrated a need for antigen-specific CD8 + T cells to induce protection against *P. berghei* sporozoite challenge infection ([@bb0930]). First clinical trials have been initiated using recombinant MVA expressing the important malaria liver stage antigens TRAP/CSP alone or in a heterologous prime-boost schedule in combination with adenoviral vectors ([@bb0385]). Further improvement of this antigen has been achieved by fusion of TRAP with a peptide sequence encompassing a Plasmodium-specific multiple epitope (ME-TRAP) ([@bb0380]). In detail, Moorthy and coworkers generated a single polypeptide ME-TRAP of 789 amino acids which combines a multiple epitope string (ME) consisting of 14 CD8 + T-cell epitopes with three CD4 + T-cell epitopes from tetanus toxin, BCG, and Pf-circumsporozoite protein (PfCSP) and two B-cell epitopes within the established TRAP antigen. Here, DNA prime and recombinant MVA boost schedules have been evaluated for safety and immunogenicity in a phase I/II clinical trial in humans. No severe adverse effects were observed after application of MVA-ME-TRAP alone or in combination with DNA prime vaccination ([@bb0765]). In following clinical evaluations, immunogenicity and protection has been assessed in African adults in a malaria-endemic area. Heterologous regimens using DNA prime and MVA boosting proved to be more immunogenic compared to homologous application of either vaccine used alone. However, despite measurable immunogenicity, robust protection against challenge with *P. falciparum* could not be detected ([@bb0765], [@bb0770]). Another advancement was based on studies that tested different combinations of primary immunizations with recombinant fowlpox and recombinant MVA vaccines ([@bb0025]). Next steps included the clinical evaluation of these malaria vaccine candidates in heterologous prime-boost vaccinations. Here, the booster immunizations resulted in an efficient activation of malaria-specific CD8 + T cells in adults and children ([@bb1135], [@bb1165]). However, efficacy testing in field studies in endemic areas failed to robustly protect against malaria infection at various stages ([@bb0070]). Another innovative approach of heterologous prime-boost vaccination has been conducted by Rodriguez and colleagues in the murine *P. berghei* infection model. The alternative usage of porcine parvovirus-like particles delivering CS protein peptide sequences resulted in efficient priming of protective CD8 + T-cell responses following booster vaccination with recombinant MVA expressing the CS antigen ([@bb0905]). More recently another heterologous prime-boost vaccination schedule has been thoroughly evaluated using chimpanzee-adenovirus vectors for priming and recombinant MVA for booster vaccinations (for review, see [@bb0935]). This combination of vector immunization induced high frequencies of ME-TRAP-specific T-cell responses in humans as a promising approach to robustly protect against *P. falciparum* ([@bb0310]). Moreover, a recent study suggested the feasibility of developing malaria transmission-blocking vector vaccines to target *P. falciparum* within the mosquito. Antibodies with high-level transmission-blocking activity could be elicited upon prime-boost immunizations of mice with recombinant chimpanzee adenovirus and MVA-expressing candidate malaria antigens Pfs230-C and Pfs25 ([@bb0565]). Thus, future approaches in the development of MVA vector vaccines against malaria aim at the induction of a more balanced immunity based on both efficient humoral and cellular immune responses. Yet, complex clinical phase II/III studies in humans in endemic areas will be needed to evaluate the efficacy of these new promising approaches.

4.4. MVA Vector Vaccines Against Emerging Infections {#s0075}
----------------------------------------------------

Newly emerging pathogens represent another global public health risk as they can suddenly and unexpectedly arise from a previously unknown ecological niche, in most cases an animal reservoir. Thus, major concerns are zoonotic infections that are transmitted from animals to humans, which, when sufficiently adapted to the human host, may rapidly spread in the human population ([@bb0625], [@bb0885], [@bb1015]). During the past 20 years, public health systems had been confronted with a multitude of new pathogens each demonstrating a different scenario of emergence. In this context, the year 1999 with the sudden occurrence of West Nile fever in the Western hemisphere (New York City, USA) is often marked as the beginning of a new era of epidemics (for review, see [@bb1040]). WNV is a member of the genus flaviviruses and, as an arbovirus, continuously circulates between different mosquito species and birds as the major animal virus reservoirs. Through the bite of an infected mosquito, WNV can be transmitted to mammalian hosts, primarily to humans or horses, causing the so-called West Nile Fever sometimes resulting in neuroinvasive disease with the potential for severe outcomes especially in elderly and immunocompromised humans. The virus had first been isolated in 1937 from a febrile woman in the West Nile District in Uganda ([@bb0410]). Since then it was observed to be or become endemic in regions of Europe, Africa, and Asia periodically causing WNV outbreaks in humans and/or horses. In 1999, the virus was introduced into the New York City District of Queens, supposedly by an infected mosquito or bird ([@bb0640], [@bb0795], [@bb0805]). Thus, WNV had relocated to a new, naïve population facilitating its impressive spread across the North American continent leading to a total of about 41,762 human infections and 1765 deaths between 1999 and 2014 (<http://www.cdc.gov/westnile/statsmaps/>). Concurrently, the virus also increasingly emerges in European countries, resulting in outbreaks of severe disease in horses and humans. Thus, a safe and effective WNV vaccine for humans is urgently needed in particular to protect at-risk populations. A recent study tested different recombinant MVA vaccines delivering the WNV envelope protein (WNV-E) and fulfilling all the principal requirements to proceed to clinical testing in humans. Vaccine immunogenicity, induction of neutralizing antibodies and E-specific CD8 + T-cell responses, and the capacity to protect against lethal challenge infections were evaluated in different mouse models. The MVA--WNV candidate vaccines allowed to compare the performance of WNV-E antigens expressed in four different conformations. In MVA-prM/ME, WNV-E is produced together with the WNV membrane protein to induce the synthesis and the release of virus like particles (VLPs) upon MVA infection. MVA-E~sol~ produces a soluble version of WNV-E that is secreted from infected cells. MVA-E~TMV~ and MVA-E~TMC~ prominently expose WNV-E antigens on the cell surface by providing heterologous transmembrane domains derived from either VACV (TMV, transmembrane domain vaccinia virus) or chikungunya virus (TMC, transmembrane domain chikungunya virus). Upon prime-boost vaccinations in BALB/c mice, all four MVA--WNV candidate vaccines elicited circulating serum antibodies binding to recombinant WNV-E protein and neutralizing WNV in tissue culture infections In addition, immunizations in HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice efficiently induced WNV-E-specific CD8 + T-cell responses. Finally, the MVA--WNV candidate vaccines protected C57BL/6 mice against challenge infections with lineage 1 and lineage 2 WNV and activated cross-neutralizing antibodies. Thus, further studies are warranted to evaluate these recombinant MVA--WNV vaccines in other preclinical models in an effort to select and develop an MVA--WNV candidate vaccine for clinical testing in humans ([@bb1120]).

Recently, the family *Coronaviridae* provided different new pathogens suddenly arising from an ecological niche. Since 2003 two novel beta coronaviruses have been introduced into human populations causing acute atypical necrotizing pneumonia, the so-called severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) ([@bb0440]). In early 2003, the SARS epidemic initially occurred in Southern China and rapidly spread to more than 37 countries causing 8096 infections and 774 deaths. Bat species and civet cats were identified as animal reservoirs transmitting the virus to humans and/or other animals. The abrupt emergence of the SARS-CoV in China in November 2002 and its worldwide distribution until the end of 2003 is representative for the scenario of a pandemic public health emergency. Luckily, further spread of the disease could be prevented and no further infections with SARS-CoV were detected since early 2004. The successful containment of SARS was likely due to multiple causes, e.g., the relative ease of clinical case isolation and the persistence of the pathogen in an animal reservoir rarely enabling transmission to humans. However, the lessons learned from SARS include the need for the timely development of specific vaccines to counteract such an outbreak scenario with high morbidity and mortality rates and the lack of any specific treatment option. The most effective approach to deal with emerging pathogens is vaccination. MVA with its excellent safety profile and well-established vector production platform holds great potential to rapidly develop new vaccines against such emerging pathogens ready to use in an immediate public health response. In an ideal scenario, MVA emergency vaccines against selected pathogens of risk are being developed and undergo preclinical and phase I/II clinical evaluations already in preepidemic times. In the case of a disease outbreak, these recombinant MVA candidate vaccines could be immediately tested in efficacy studies when used to vaccinate people of special risk in endemic areas. This concept already spurred the development of a first set of recombinant MVA candidate vaccines against highly pathogenic avian influenza viruses and the recently emerging MERS-CoV as current examples of new zoonotic agents. MERS-CoV was first described in September 2012. In contrast to experiences with SARS in the epidemic of 2002/2003, the MERS-CoV continues to cause disease in humans in the fifth year after its first appearance in 2012. At present, WHO reports a total of 1782 laboratory confirmed cases including 634 deaths (<http://www.who.int/emergencies/mers-cov/en/>). The epidemiology of human MERS-CoV infections centers in the Middle East, e.g., in Qatar, Saudi Arabia, Jordan, and United Arab Emirates. Sporadically, MERS-CoV infections are also spread to other countries in Europe, North-America, and Asia due to transmission by travelers infected in the Middle East. Raj and coworkers identified the human cell surface amino peptidase dipeptidyl 4 or CD26 as functional receptor of MERS-CoV-mediating entry into the cell ([@bb0870]). By now dromedary camels are known and generally accepted to be the critical animal reservoir responsible for spreading the virus to humans ([@bb0450], [@bb0735], [@bb0755], [@bb0875]). These primary zoonotic infections can result in interfamilial or health care related secondary transmissions. The elderly and immunocompromised persons are among the people of risk to suffer most from severe and lethal MERS-CoV infections. Other individuals at risk are health care workers and people with close contact to camels. All these groups are considered relevant target populations for potential MERS-CoV vaccines. So far, there is no licensed vaccine against MERS-CoV or SARS-CoV available. Different approaches have been undertaken to develop effective means to prevent or cure these new infectious diseases. Here, MVA has been tested as viral vector vaccine against both beta coronaviruses. The envelope spike (S) protein has been proven to be a major target of SARS-CoV-neutralizing antibodies ([@bb0470], [@bb1035]). Indeed, a recombinant MVA producing the SARS-CoV S antigen was evaluated in different animal models and demonstrated the induction of SARS-CoV-specific immune responses, including SARS-CoV-neutralizing antibodies and S-antigen-specific T cells in mice, rabbits, and rhesus macaques ([@bb0085], [@bb0165]). Prime boost immunization effectively inhibited SARS-CoV replication in cynomolgous monkeys after respiratory SARS-CoV challenge infection suggesting the induction of protective immunity. In the case of the MERS-CoV, a recombinant MVA expressing the S protein of MERS-CoV (MVA-MERS-S) was generated rapidly after the discovery of MERS in 2012 ([@bb0970]). Here, the MERS-CoV-S-encoding sequences were introduced into the deletion site III of the MVA genome. Preclinical evaluation of MVA-MERS-S candidate vaccine confirmed the induction of MERS-CoV-neutralizing antibodies and MERS-S epitope-specific CD8 + T cells in BALB/c mice comparing different dosages and application routes ([@bb1115]). Moreover, preclinical testing in a special mouse model allowed for the first demonstration of the protective capacity of this MERS candidate vaccine. After adenovirus-mediated transduction with the human dipeptidylpeptidase 4 receptor, BALB/c mice are susceptible for respiratory MERS-CoV challenge infections and the monitoring of virus loads allows to determine the efficacy of experimental immunization ([@bb1230]). As the virus is assumed to persist in dromedary camels, further preclinical analysis in dromedary camels demonstrated immunogenicity and protective efficacy of MVA-MERS-S ([@bb0455]). Simultaneous immunizations by the intranasal and intramuscular routes resulted in efficient induction of virus-neutralizing antibodies in serum and nasal secretions of vaccinated animals. Contrary to the mock vaccinated control animals, camels vaccinated with MVA-MERS-S revealed a significant reduction of excreted infectious virus and viral RNA transcripts after MERS-CoV challenge infection. In addition, vaccination with MVA-MERS-S also induced the activation of orthopoxvirus-specific antibodies that readily cross-neutralized camelpox virus. Camelpox virus causes severe systemic disease in camels with case fatality rates as high as 28%. Clinical disease is characterized by papules and pustules that initially appear at the primary site of infection. This is then followed by the development of generalized rash and fever between day 9 and 11 postinfection. Young camels are more susceptible to severe clinical disease. The activation of camelpox virus-neutralizing antibodies suggested the potential dual use of this candidate MERS-CoV vaccine in dromedaries to efficiently protect against MERS-CoV and camelpox virus infection ([@bb0455]). These data further support the general safety and efficacy of the MVA-MERS-S candidate vaccine and introduce the possibility for application as veterinary vaccine with important implications to the One Health concept. Vaccination of dromedary camels in areas endemic for MERS-CoV could reduce the burden of virus excretions from the animal reservoir and thus inhibit the transmission of MERS-CoV to human populations. In addition, it is important to characterize the MVA-MERS-S candidate vaccine in humans and efforts are ongoing to start a first-in-man clinical evaluation of MVA-MERS-S as soon as possible. In this first clinical phase I/II testing, safety and immunogenicity of the MVA-MERS-S candidate vaccine will be analyzed in healthy volunteers in Germany. Results from these phase I/II clinical evaluations are prerequisite for testing the vaccine in larger phase II studies in endemic countries. In addition, the availability of an investigational drug batch of MVA-MERS-S might allow for application of as emergency vaccine in the case of a suddenly occurring outbreak scenario, when the virus is rapidly transmitted and spread throughout a new geographic area. Exemplary for this was the introduction of MERS-CoV to South Korea on 20 May 2015 ([@bb0760]). A 68-year-old man returning from the Middle East had been diagnosed with MERS 9 days after he initially visited the hospital for medical help. In the hospital further spread of MERS-CoV occurred by transmission to several health care workers and other patients. In this outbreak, a total of 186 individuals have been infected, with a total of 36 deaths. In this context, the government of the Republic of Korea began to implement intense case and contact management activities that in the end stopped the epidemic of MERS-CoV in a nonendemic region. However, the sudden and rapid spread of MERS-CoV in South Korea again highlighted the global risks of newly emerging pathogens that might unexpectedly threaten a naïve population ([@bb0540], [@bb0575]).

Another very recent example for the sudden reemergence of a highly infectious pathogen is the unprecedented Ebola virus epidemic in West Africa starting in 2013 and continuing for over 2 years. During this devastating and most widespread Ebola virus outbreak, the virus had caused more than 28,000 disease cases and 11,325 deaths mainly geographically linked to the Africa but some cases were also diagnosed in travelers from Africa to the United States, Germany, France, Spain, and Great Britain ([@bb0210], [@bb0865]). Initially, this large epidemic began in the village of Meliandou, Guéckédou Prefecture, Guinea in the end of 2013. Most likely bats transmitted the virus to humans followed by massive spread of the disease to other villages. Moreover, the virus causing this outbreak was identified to be the most notorious member of the genus Ebolavirus and the species Zaire Ebolavirus (EBOV) ([@bb0050]). In consequence, the epidemic in West Africa was associated with high morbidity and mortality rates that enabled an undamped transmission and perpetuation of the virus in the population for a rather long time period ([@bb0395]). This had not been observed for Ebolavirus outbreaks in the past. So far, there are no efficient therapeutics available ([@bb0170]) and there are also no vaccines licensed to protect against Ebolavirus. However, since this very recent epidemic, research activities to develop and evaluate candidate vaccines against Ebolavirus have been intensified. Most promising candidates already advanced to clinical evaluation in humans, and include a recombinant Vesicular Stomatitis Virus (VSV) delivering the Ebolavirus Zaire glycoprotein (VSV-EBOV) and a chimpanzee-adenovirus (ChAd3)-Zaire Ebola virus (ZEBOV) also expressing the Ebolavirus Zaire glycoprotein as target antigen. With regard to the ChAd3-Zaire, the strategy is to use a heterologous prime-boost immunization schedule, boosting with an appropriate recombinant MVA-expressing Ebolavirus Zaire glycoprotein ([@bb0315], [@bb1070]). This strategy was supported by data from the preclinical evaluation of a ChAd3-EBOV candidate vaccine in nonhuman primates. Here, prime-boost vaccination with the ChAd3-EBOV vaccine alone did not confer protective immunity over a period of several months. However, robust protection against lethal challenge with EBOV could be obtained following booster vaccination with a recombinant MVA-EBOV candidate vaccine coexpressing the Ebolavirus Zaire and Sudan glycoproteins under the control of the P7.5 vaccinia virus early promoter ([@bb1010]). The approach of using a ChAd3-EBOV prime and MVA-EBOV boost vaccination has been further developed by the engineering of a multivalent recombinant MVA coproducing the ZEBOV and Sudan Ebola virus glycoproteins and other filovirus antigens (MVA-BN-Filo). A first phase Ib clinical study demonstrated safety, tolerability, and immunogenicity of the ChAd3-EBOV prime and MVA-BN-Filo booster immunizations in adults in the United States and in Mali. Without any observation of severe side effects the combined ChAd3-EBOV and MVA-BN-Filo vaccinations proved to be highly immunogenic as it was shown by the activation of EBOV-specific antibodies and CD4 + and CD8 + T-cell responses ([@bb1070]). Ewer and colleagues investigated another heterologous prime-boost vaccination schedule in 60 healthy adult volunteers in Oxford, United Kingdom, using a ChAd3 vector vaccine and a monovalent recombinant MVA encoding the surface glycoprotein of ZEBOV. Again, ChAd3 immunization boosted with MVA-elicited B-cell and T-cell immune responses to ZEBOV that were clearly superior to those induced by the ChAd3 vector vaccine alone ([@bb0315]). Nevertheless, a heterologous vaccination strategy with two different viral vector vaccines is a complex regimen to be applied in large field studies or in the case of emergency vaccination when whole populations have to be protected rapidly. Thus, it should be interesting to evaluate the efficacy of a prime-boost vaccination scheme based on MVA-EBOV only. In summary, the highly versatile and safe MVA vector platform should be particularly useful to effectively control newly emerging or reemerging infectious diseases. The vector system may be readily exploited in a plug-and-play generic approach for the rapid generation of vaccine candidates suitable for rapid emergency immunization and, simultaneously, the clinical-stage development of a new licensable product.

5. MVA as Third-Generation Vaccine Against Smallpox {#s0080}
===================================================

Eradication of human smallpox has been achieved by prophylactic use of VACV to immunize humans, the only host reservoir of the causative agent VARV. However, other members of the genus Orthopoxvirus can cause zoonotic infections ([@bb0620], [@bb0710], [@bb1130]). Moreover, recent fears that monkeypox virus (MPXV) or VARV could be used as biological weapons have renewed the interest in safe vaccines against VARV or other zoonotic orthopoxviruses ([@bb0780]). MVA holds great promise for worldwide use as third-generation smallpox vaccine due to its well-established characteristics concerning safety and immunogenicity ([@bb0260], [@bb0550], [@bb0580], [@bb0745], [@bb1085], [@bb1205]). In 2013, an MVA vaccine has been licensed in Europe for active immunization against smallpox in adults and for use in situations where it is considered necessary to protect against smallpox in accordance with official recommendations ([@bb0305]). Data from multiple phase II clinical studies have confirmed the safety and immunogenicity of the MVA vaccine in patient populations considered at risk for conventional smallpox vaccination including individuals with atopic dermatitis or HIV infection ([@bb0445], [@bb0835], [@bb1125]). In addition, MVA has been successfully tested for cardiac safety in a large phase II clinical trial ([@bb1240]). This is important because vaccines based on replication-competent VACV strains are associated with a high incidence of myo-/pericarditis, a severe cardiac complication. Additional recent data from clinical studies addressed the meta-analysis of MVA-induced immune responses in various patient populations and the comparative evaluation of inoculation routes or improved formulations of the MVA vaccine ([@bb0355], [@bb1090]). Today, with the eradication of smallpox, we lack an established human disease representing the pathogenesis of a systemic orthopoxvirus infection in humans. Therefore, analyzing the protective efficacy of orthopoxvirus-specific vaccines is not straightforward. Preclinical evaluations in animal models are required to test vaccine-mediated protection in relation to antigen-specific responses, and animal models must mimic the target poxvirus diseases in humans as closely as possible. VARV infection in cynomolgus macaques can result in a lethal disease with similarities to smallpox ([@bb0535], [@bb1140]). However, VARV is a biosafety level 4 agent and the handling with this virus is highly restricted. Thus, several other animal models using the orthopoxviruses cowpox virus (CPXV), MPXV, ectromelia virus (ECTV), and VACV have been developed ([@bb0160], [@bb0300]). MVA, as safe smallpox vaccine, has been tested in these different infection models. MVA vaccination by the intramuscular or subcutaneous route protected mice against severe respiratory challenge infection with CPXV or VACV-WR ([@bb0185], [@bb0260]). Of note, MVA could also protect mice lacking several components of the immune system, resembling high-risk groups in the population that would require an alternative to the standard smallpox vaccine ([@bb1205]). In nonhuman primates, the challenge infection with MPXV is the most appropriate model to evaluate the preclinical efficacy of new candidate smallpox vaccines. Here, a standard dosage of 10^8^  pfu MVA robustly protected cynomolgous monkeys against intravenous or intratracheal MPXV challenges ([@bb0280], [@bb1030]). In this context Edghill-Smith and coworkers demonstrated the essential need of antibodies for protection against fatal monkeypox disease ([@bb0285]). One major limitation in these orthopoxvirus infection models, using VACV, MPXV, or CPXV to test protective capacity of vaccination, is the high amounts of infectious virus (\> 10^6^  pfu) required to induce lethal disease. In contrast, very few infectious particles of VARV could generate fatal smallpox disease in naive humans. To overcome this shortcoming, the ECTV infection of mice can serve as an additional highly appropriate model for the reassessment of the correlates of protective immunity (for review [@bb0945]). ECTV, the causative agent of mousepox, is a natural mouse pathogen causing a classical systemic poxvirus disease ([@bb0300]). Very low amounts of ECTV are sufficient for infection and induction of lethal mousepox disease in susceptible mouse strains. After an asymptomatic incubation period of 6--8 days following intranasal infection, mousepox disease starts in the respiratory tract followed by a systemic virus spread to internal organs such as liver and spleen ([@bb0845], [@bb0850]). Specific signs of illness are characterized by severe bronchopneumonia and hepatitis. Mice that survive this systemic phase of severe disease develop a characteristic pustular rash on the skin very reminiscent to that seen in human smallpox. The ECTV-mouse model offers the opportunity to study an orthopoxvirus pathogen in an experimentally easily accessible natural host. ECTV is highly adapted to the mouse immune system and this allows to thoroughly analyze the mechanisms of viral immune evasion and vaccine-induced immune protection. Several studies evaluated MVA vaccine-mediated protection against lethal mousepox disease in more detail. Coulibaly and coworkers demonstrated the usefulness of respiratory ECTV challenge infections as improved model system for efficacy testing. Here, intramuscular immunization with a single dose of 10^6^  pfu MVA prevented severe disease and death in mice challenged 3 weeks after vaccination. A single dose of 10^7^ robustly protected against any signs of illness and disease after the respiratory mousepox challenge. However, after vaccination with 10^6^ or 10^7^  pfu VACV Wyeth, all mice suffered from severe lethal disease ([@bb0185]). In the CPXV challenge model, these different candidate vaccines were equally protective underlining the impact of choosing a specific challenge virus. This study demonstrates the need for data from various preclinical models as key component in developing next-generation orthopoxvirus-specific vaccines for application in humans. In the case of an emergency with newly arising highly pathogenic orthopoxviruses, e.g., because of unintentional or intentional release of VARV, vaccination protocols for rapid induction of protective immunity are urgently needed ([@bb0880], [@bb0925]). For smallpox vaccination there are historical reports that VACV application in a time window of up to 4 days after exposure with VARV may be protective. Analysis of MVA as emergency vaccine confirmed short-term protective capacity of vaccination in mice, latest when applied at the day of the lethal respiratory challenge with VACV strain WR. Postexposure prophylaxis could not be achieved in the VACV-WR model, independent of dosage and application route ([@bb1005]). However, when testing emergency vaccination in the ECTV-mouse model, a standard dosage of 10^8^  pfu MVA robustly protected against lethal respiratory mousepox infection up to 2 days before the challenge. Even more, in this natural virus--host system, 10^8^  pfu MVA also prevented death and severe disease when applied up to 4 days after the lethal challenge. However, postexposure vaccination could not inhibit the onset of sign of disease including respiratory symptoms and body weight loss ([@bb0845]). In a follow-up study, Kremer and colleagues analyzed the immune components mediating this rapid protection in more detail ([@bb0610]). Analysis of MVA-induced protection in mice with defined deficiency in the innate or adaptive immunity identified CD4 + T cells to be essentially required to allow for MVA-induced CD8 + T-cell expansion. Interestingly, selected components of the innate immune system and B cell-mediated responses were fully dispensable for prevention of fatal disease by immunization given 2 days before challenge. Analyzing protective capacity of MVA immunization in RAG −/− mice that lack T cells and B cells, these mice could not be protected against the lethal ECTV challenge infection. These results underlined the prerequisite of adaptive cellular immunity for mediating a rapid protection with perforin-mediated cytotoxicity proven to be a key immune mechanism. In the case of emergency, when rapid induction of protective immunity by vaccination is desirable for prevention of morbidity and mortality, the instant activation of protective virus-specific immunity by single-shot vaccination, would be ideal. Moreover, the possibilities of dose-sparing immunization regimens would increase the numbers of people that can be vaccinated. Volz and coworkers assessed the minimal requirements for the induction of protective immunity against lethal ECTV challenge infection 2 days after immunization with MVA ([@bb1110]). C57BL/6 mice had been intramuscularly vaccinated with tenfold increasing doses of MVA starting with 10^3^ up to 10^8^  pfu, the MVA standard dosage. Interestingly, a minimal amount of 10^5^  pfu fully protected the mice against the lethal respiratory challenge infection with ECTV. Moreover, inoculations with 10^4^  pfu MVA were still sufficient to prevent death of all vaccinated animals but could not protect against the induction of mousepox disease. Analysis of immune responses again identified CD8 + T cells as the key components mediating the rapid protection in the low dose immunization model. Moreover, MVA immunization at low dosage also protected IFNAR −/− mice, indicating efficient activation of cellular immunity even in the absence of type I IFN signaling. When monitoring for virus-specific CD8 + T-cell responses in mice vaccinated with the minimal protective dose of MVA, we found significantly enhanced levels of antigen-specific T cells in animals that were MVA vaccinated and ECTV challenged compared to mice that were only vaccinated. The initial priming of naïve CD8 + T cells by MVA immunization appears to be highly efficient and, even at low doses, mediates a rapid in vivo burst of pathogen-specific CD8 + T cells upon challenge. These findings define striking requirements for protective emergency immunization against severe systemic infections with orthopoxviruses. These data are of important practical relevance for public health, as producing sufficient amounts of vaccine is expected to be a major challenge should an outbreak occur. Moreover, prevention of other infections may require similar immune mechanisms to elicit rapid protective immunity; hence, MVA could be an extremely useful vaccine for delivering heterologous T cell antigens, particularly for infectious diseases that fit a scenario of emergency vaccination. Thus, studies evaluating recombinant MVA candidate vaccines as emergency vaccines might be promising for the development of new prophylactic or therapeutic approaches.

6. Conclusions {#s0085}
==============

Today, almost 40 years after its first licensing in Germany, MVA is well established as safety-tested, immunogenic, and efficacious third-generation smallpox vaccine. In 2013, the European Medicines Agency and Canada Health granted the marketing authorization of an MVA vaccine to immunize against VARV infection, in the absence of human smallpox or naturally occurring VARV ([@bb0305]). Thus, efficacy data needed to be generated from animal models of orthopoxvirus infections considered to be representative for human smallpox. A similar licensing process by the US Food and Drug Administration is ongoing and appears to be at an advanced stage. Despite the eradication of VARV more than three decades ago, these efforts are still important mostly due to the threat of VARV being---accidently or intentionally---released into unprotected human populations. Moreover, the use of a licensed MVA vaccine should be ideal to protect individuals at risk---including laboratory workers---against other zoonotic orthopoxviruses such as CPXV and MPXV that continue to cycle in rodent reservoirs and can cause disease in humans.

In addition, during 25 years, MVA has been continuously improved as an extremely safe and efficient viral vector system for the synthesis of high levels of foreign proteins in nonpermissive human cells. At the moment, recombinant MVA viruses expressing various heterologous antigens are among the most promising vector candidates to develop innovative vaccination strategies to protect against complex infections such as AIDS, tuberculosis, or malaria, or against rare but threatening emerging diseases. Desirable common characteristics of MVA as viral vector vaccine include the genetic stability, the well-established production procedures and the general safety for the environment. Results coming from clinical testing of various recombinant MVA vaccines further emphasize its excellent safety record and its immunogenicity as vaccine in humans. In the context of recent clinical findings, it is noteworthy that repeated vaccinations with the same recombinant MVA resulted in substantial booster induction of antigen-specific antibodies even in the presence of high levels of MVA-specific immunity. These results together with other promising data gained from the combined application of MVA with various other viral vector platforms greatly enhance the general acceptance of viral vectors as next-generation candidate vaccines. In addition to its promising characteristics concerning immunogenicity, the nonreplicating recombinant MVA vaccines are also well positioned to satisfy very stringent requirements for a broad safety in various settings. MVA vaccines appear highly suitable for use in immunocompromised individuals and in the elderly representing important target populations in ever-ageing populations in the industrialized world. At the same time, recombinant MVA should be also safe to immunize persons with severe comorbidities, e.g., HIV infection, tuberculosis, or malaria, as it is often seen in developing nations. New vaccines that rapidly protect against threatening emerging pathogens are urgently needed. This it is further highlighted by the WHO-list of the "top most wanted" emerging diseases likely to cause major epidemics. Here, the longstanding experience with the MVA vector vaccine platform in preclinical and clinical research should lead to important contributions to the development of protective vaccination strategies against newly emerging pathogens.

Finally, the exciting results from ongoing fundamental research on the biology of MVA spur the possibility to even improve the efficacy of future MVA vaccines. Here, an exemplary area of research targets the still unknown functions of host-regulatory genes remaining conserved in the MVA genome. Indeed, modulating the functional activity of these regulatory MVA proteins could be beneficial in enhancing the immunogenicity of MVA vaccines and activate innate and/or adaptive immune responses to heterologous antigens.
